Yuichi Honma1, Michihiko Shibata2, Kahori Morino2, Yudai Koya2,3, Tsuguru Hayashi2, Noriyoshi Ogino2, Masashi Kusanaga2, Shinji Oe2, Koichiro Miyagawa2, Shintaro Abe2, Akinari Tabaru2,4, Masaru Harada2. 1. Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, 807-8555, Japan. y-homma@med.uoeh-u.ac.jp. 2. Third Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, 807-8555, Japan. 3. Department of Gastroenterology, Moji Medical Center, 3-1 Higashiminato-machi, Moji-ku, Kitakyushu, 801-8502, Japan. 4. Department of Gastroenterology, Wakamatsu Hospital of the University of Occupational and Environmental Health, 1-17-1 Hama-machi, Wakamatsu-ku, Kitakyushu, 800-0024, Japan.
Abstract
BACKGROUND: The incidence of extrahepatic malignancies (EHMs) after hepatitis C virus (HCV) eradication by interferon (IFN)-based and IFN-free direct-acting antivirals (DAAs) treatment remains unclear. AIMS: The aim was to evaluate the cumulative incidence of EHMs diagnosed for the first time after the antiviral treatments. METHODS: We analyzed a total 527 patients with chronic HCV infection and without prior history of any malignancies who achieved sustained virological response by antiviral treatments, including IFN-based (n = 242) or IFN-free DAAs (n = 285). The baseline predictors for EHM occurrence were analyzed using Cox regression analysis. RESULTS: Thirty-two patients were diagnosed with EHMs, 14 in IFN-based and 18 in IFN-free DAAs, respectively. The total duration of follow-up was 1,796 person-years in IFN-based and 823 person-years in IFN-free DAAs. The incidence of EHMs in IFN-based and IFN-free DAAs was 7.8 and 21.9 per 1,000 person-years, respectively. The cumulative incidence of EHMs was significantly higher in IFN-free DAAs than IFN-based (p = 0.002). IFN-free DAAs was a single independent predictor for incidence of EHMs (p = 0.012). As for gender, the incidence of EHMs was significantly higher in IFN-free DAAs only in the female cohort (p = 0.002). After propensity score matching, IFN-free DAAs was a single independent predictor for incidence of EHMs in the female patients (p = 0.045). CONCLUSIONS: The incidence of EHMs after HCV eradication is higher in IFN-free DAAs than IFN-based regimens, especially in female patients. We should carefully follow-up not only HCC but also EHMs after IFN-free DAAs regimens.
BACKGROUND: The incidence of extrahepatic malignancies (EHMs) after hepatitis C virus (HCV) eradication by interferon (IFN)-based and IFN-free direct-acting antivirals (DAAs) treatment remains unclear. AIMS: The aim was to evaluate the cumulative incidence of EHMs diagnosed for the first time after the antiviral treatments. METHODS: We analyzed a total 527 patients with chronic HCV infection and without prior history of any malignancies who achieved sustained virological response by antiviral treatments, including IFN-based (n = 242) or IFN-free DAAs (n = 285). The baseline predictors for EHM occurrence were analyzed using Cox regression analysis. RESULTS: Thirty-two patients were diagnosed with EHMs, 14 in IFN-based and 18 in IFN-free DAAs, respectively. The total duration of follow-up was 1,796 person-years in IFN-based and 823 person-years in IFN-free DAAs. The incidence of EHMs in IFN-based and IFN-free DAAs was 7.8 and 21.9 per 1,000 person-years, respectively. The cumulative incidence of EHMs was significantly higher in IFN-free DAAs than IFN-based (p = 0.002). IFN-free DAAs was a single independent predictor for incidence of EHMs (p = 0.012). As for gender, the incidence of EHMs was significantly higher in IFN-free DAAs only in the female cohort (p = 0.002). After propensity score matching, IFN-free DAAs was a single independent predictor for incidence of EHMs in the female patients (p = 0.045). CONCLUSIONS: The incidence of EHMs after HCV eradication is higher in IFN-free DAAs than IFN-based regimens, especially in female patients. We should carefully follow-up not only HCC but also EHMs after IFN-free DAAs regimens.
Authors: Francesco Negro; Daniel Forton; Antonio Craxì; Mark S Sulkowski; Jordan J Feld; Michael P Manns Journal: Gastroenterology Date: 2015-08-28 Impact factor: 22.682
Authors: Robert D Allison; Xin Tong; Anne C Moorman; Kathleen N Ly; Loralee Rupp; Fujie Xu; Stuart C Gordon; Scott D Holmberg Journal: J Hepatol Date: 2015-05-01 Impact factor: 25.083
Authors: S De Vita; V De Re; D Sansonno; D Sorrentino; R L Corte; B Pivetta; D Gasparotto; V Racanelli; A Marzotto; A Labombarda; A Gloghini; G Ferraccioli; A Monteverde; A Carbone; F Dammacco; M Boiocchi Journal: Hepatology Date: 2000-01 Impact factor: 17.425
Authors: J J Arrieta; E Rodriguez-Inigo; M Casqueiro; J Bartolomé; F Manzarbeitia; M Herrero; M Pardo; V Carreno Journal: Hepatology Date: 2000-07 Impact factor: 17.425
Authors: A L Zignego; D Macchia; M Monti; V Thiers; M Mazzetti; M Foschi; E Maggi; S Romagnani; P Gentilini; C Bréchot Journal: J Hepatol Date: 1992-07 Impact factor: 25.083